Dendritic cells (DCs) excel at cross-presenting antigens, but their effectiveness as cancer vaccine is limited. Here, we describe an innovative vaccine approach using mesenchymal stromal cells (MSCs) engineered to express the immunoproteasome (IPr) complex (MSC-IPr). Such modification instilled efficient antigen cross-presenting abilities associated with enhanced major histocompatibility complex (MHC)I and CD80 expression, de novo expression of interleukin-12 along with higher chemokine secretion. In addition, the cross-presentation capacity of MSC-IPr is highly dependent on AMPK signaling, oxidative phosphorylation and production of reactive oxygen species. Compared to DCs, MSC-IPr hold the ability to cross-present a vastly different epitope repertoire, which translates into potent re-activation of T-cell immunity against EL4 lymphoma and B16 melanoma tumors. Moreover, therapeutic vaccination of animals with pre-established tumors efficiently controls cancer growth, an effect further enhanced when combined with antibodies targeting PD1, CTLA4, LAG3 or 4-1BB under both autologous and allogeneic settings. MSC-IPr constitute therefore a novel subset of non-hematopoietic antigen-presenting cells suitable for the future design of universal cell-based cancer vaccines.
Abusarah, Jamilah and Khodayarian, Fatemeh and El-Hachem, Nehme and Salame, Natasha and Olivier, Martin and Balood, Mohammad and Roversi, Katiane and Talbot, Sebastien and Bikorimana, Jean-Pierre and Chen, Jingkui and Jolicoeur, Mario and Trudeau, Louis-Eric and Kamyabiazar, Samaneh and Annabi, Borhane and Robert, Francis and Pelletier, Jerry and El-Kadiry, Abed and Shammaa, Riam and Rafei, Moutih, Engineering a Potent Cancer Vaccine Using Immunoproteasome-Expressing Mesenchymal Stromal Cells. Available at SSRN: https://ssrn.com/abstract=3782860 or http://dx.doi.org/10.2139/ssrn.3782860
This version of the paper has not been formally peer reviewed.
Subscribe to this free journal for more curated articles on this topic
FOLLOWERS
16
PAPERS
7,408
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.